143 related articles for article (PubMed ID: 11748454)
1. Expression of CD44s and CD44 splice variants in human melanoma.
Ranuncolo SM; Ladeda V; Gorostidy S; Morandi A; Varela M; Lastiri J; Loria D; Del Aguila R; Joffé EB; Pallotta G; Puricelli L
Oncol Rep; 2002; 9(1):51-6. PubMed ID: 11748454
[TBL] [Abstract][Full Text] [Related]
2. CD44 expression in sinonasal melanomas: is loss of isoform expression associated with advanced tumour stage?
Regauer S; Ott A; Berghold A; Beham A
J Pathol; 1999 Jan; 187(2):184-90. PubMed ID: 10365093
[TBL] [Abstract][Full Text] [Related]
3. Expression of the CD44 cell adhesion molecule in urinary bladder transitional cell carcinoma.
Ross JS; del Rosario AD; Bui HX; Kallakury BV; Okby NT; Figge J
Mod Pathol; 1996 Aug; 9(8):854-60. PubMed ID: 8871928
[TBL] [Abstract][Full Text] [Related]
4. Reduced level of CD44 and hyaluronan associated with unfavorable prognosis in clinical stage I cutaneous melanoma.
Karjalainen JM; Tammi RH; Tammi MI; Eskelinen MJ; Agren UM; Parkkinen JJ; Alhava EM; Kosma VM
Am J Pathol; 2000 Sep; 157(3):957-65. PubMed ID: 10980134
[TBL] [Abstract][Full Text] [Related]
5. Expression of E-cadherin, and CD44s and CD44v6 and its association with prognosis in head and neck cancer.
Kawano T; Nakamura Y; Yanoma S; Kubota A; Furukawa M; Miyagi Y; Tsukuda M
Auris Nasus Larynx; 2004 Mar; 31(1):35-41. PubMed ID: 15041052
[TBL] [Abstract][Full Text] [Related]
6. Reduced CD44 standard expression is associated with tumour recurrence and unfavourable outcome in differentiated thyroid carcinoma.
Böhm JP; Niskanen LK; Pirinen RT; Kiraly K; Kellokoski JK; Moisio KI; Eskelinen MJ; Tulla HE; Hollmen S; Alhava EM; Kosma VM
J Pathol; 2000 Nov; 192(3):321-7. PubMed ID: 11054715
[TBL] [Abstract][Full Text] [Related]
7. Clinicopathologic significance of expression of CD44s and CD44v6 isoforms in squamous cell carcinoma of the supraglottic larynx.
Rodrigo JP; Domínguez F; Alvarez C; González MV; Herrero A; Suárez C
Am J Clin Pathol; 2002 Jul; 118(1):67-72. PubMed ID: 12109858
[TBL] [Abstract][Full Text] [Related]
8. Reduced expression of CD44v3 variant isoform is associated with unfavorable outcome in non-small cell lung carcinoma.
Pirinen R; Hirvikoski P; Böhm J; Kellokoski J; Moisio K; Virén M; Johansson R; Hollmén S; Kosma VM
Hum Pathol; 2000 Sep; 31(9):1088-95. PubMed ID: 11014576
[TBL] [Abstract][Full Text] [Related]
9. Expression of CD44 standard and variant-v6 proteins in transitional cell bladder tumours and their relation to prognosis during a long-term follow-up.
Lipponen P; Aaltoma S; Kosma VM; Ala-Opas M; Eskelinen M
J Pathol; 1998 Oct; 186(2):157-64. PubMed ID: 9924431
[TBL] [Abstract][Full Text] [Related]
10. CD44 and variants in melanocytic skin neoplasms.
Schaider H; Soyer HP; Heider KH; Hofmann-Wellenhof R; Zatloukal K; Smolle J; Kerl H
J Cutan Pathol; 1998 Apr; 25(4):199-203. PubMed ID: 9609138
[TBL] [Abstract][Full Text] [Related]
11. Prognostic significance of CD44s expression in biliary tract cancers.
Lee SM; Lee KE; Chang HJ; Choi MY; Cho MS; Min SK; Lee HK; Mun YC; Nam EM; Seong CM; Lee SN
Ann Surg Oncol; 2008 Apr; 15(4):1155-60. PubMed ID: 18214619
[TBL] [Abstract][Full Text] [Related]
12. Expression of standard CD44 in human colorectal carcinoma: association with prognosis.
Huh JW; Kim HR; Kim YJ; Lee JH; Park YS; Cho SH; Joo JK
Pathol Int; 2009 Apr; 59(4):241-6. PubMed ID: 19351367
[TBL] [Abstract][Full Text] [Related]
13. CD44s expression is associated with improved survival in soft tissue sarcoma.
Peiper M; Sato T; Zurakowski D; Eisenberger C; Heinecke A; Hosch S; Knoefel WT
Anticancer Res; 2004; 24(2C):1053-6. PubMed ID: 15154622
[TBL] [Abstract][Full Text] [Related]
14. CD44 expression is associated with increased survival in node-negative invasive breast carcinoma.
Diaz LK; Zhou X; Wright ET; Cristofanilli M; Smith T; Yang Y; Sneige N; Sahin A; Gilcrease MZ
Clin Cancer Res; 2005 May; 11(9):3309-14. PubMed ID: 15867228
[TBL] [Abstract][Full Text] [Related]
15. Expression of the hyaluronan receptor, CD44S, in epithelial ovarian cancer is an independent predictor of survival.
Kayastha S; Freedman AN; Piver MS; Mukkamalla J; Romero-Guittierez M; Werness BA
Clin Cancer Res; 1999 May; 5(5):1073-6. PubMed ID: 10353740
[TBL] [Abstract][Full Text] [Related]
16. Expression and prognostic value Of CD44 isoforms in nephroblastoma (Wilms tumor).
Ghanem MA; Van Steenbrugge GJ; Van Der Kwast TH; Sudaryo MK; Noordzij MA; Nijman RJ
J Urol; 2002 Aug; 168(2):681-6. PubMed ID: 12131349
[TBL] [Abstract][Full Text] [Related]
17. Role of CD44s and CD44v6 on human breast cancer cell adhesion, migration, and invasion.
Afify A; Purnell P; Nguyen L
Exp Mol Pathol; 2009 Apr; 86(2):95-100. PubMed ID: 19167378
[TBL] [Abstract][Full Text] [Related]
18. Clinicopathologic significance of dysadherin expression in cutaneous malignant melanoma: immunohistochemical analysis of 115 patients.
Nishizawa A; Nakanishi Y; Yoshimura K; Sasajima Y; Yamazaki N; Yamamoto A; Hanada K; Kanai Y; Hirohashi S
Cancer; 2005 Apr; 103(8):1693-700. PubMed ID: 15751018
[TBL] [Abstract][Full Text] [Related]
19. Decreased CD44 standard form expression correlates with prognostic variables in ovarian carcinomas.
Ross JS; Sheehan CE; Williams SS; Malfetano JH; Szyfelbein WM; Kallakury BV
Am J Clin Pathol; 2001 Jul; 116(1):122-8. PubMed ID: 11447742
[TBL] [Abstract][Full Text] [Related]
20. Quantitative assessment of expression of cell adhesion molecule (CD44) splice variants: CD44 standard (CD44s) and v5, v6 isoforms in oral leukoplakias: an immunohistochemical study.
Godge PY; Poonja LS
Indian J Dent Res; 2011; 22(3):493-4. PubMed ID: 22048598
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
